1 2	Physician-confirmed and administrative definitions of stroke in UK Biobank reflect the same underlying genetic trait
3 4 5	Kristiina Rannikmäe ^{*1} , Konrad Rawlik ^{*2} , Amy C Ferguson ¹ , Nikos Avramidis ³ , Muchen Jiang ⁴ , Nicola Pirastu ⁵ , Xia Shen ^{5,6,7} , Emma Davidson ⁸ , Rebecca Woodfield ⁹ , Rainer Malik ¹⁰ , Martin Dichgans ^{10,11,12} , Albert Tenesa ^{*1,2,13} , Cathie Sudlow ^{*1,14}
6	*These authors contributed equally
7	1. Centre for Medical Informatics, Usher Institute, University of Edinburgh, Edinburgh, UK
8	2. Roslin Institute, University of Edinburgh, Edinburgh, UK
9	3. School of Biological Sciences, University of Edinburgh, Edinburgh, UK
10	4. Medical School, University of Edinburgh, Edinburgh, UK
11	5. Usher Institute, University of Edinburgh, Edinburgh, UK
12	6. Biostatistics Group, School of Life Sciences, Sun Yat-sen University, Guangzhou, China
13	7. Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
14	8. Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK
15	9. Department of Medicine for the Elderly, Western General Hospital, Edinburgh, UK
16 17	10. Institute for Stroke and Dementia Research (ISD), University Hospital, LMU Munich, Munich, Germany
18	11. Munich Cluster for Systems Neurology, Munich, Germany
19	12. German Center for Neurodegenerative Diseases (DZNE), Munich, Germany
20 21	13. MRC Human Genetics Unit, Institute of Genetics and Cancer, University of Edinburgh, Western General Hospital, Edinburgh, UK.
22	14. BHF Data Science Centre, Health Data Research UK, London, UK
23 24	Grant numbers: MR/S004130/1; BHF award RE/18/5/34216; HDR-UK awards HDR-9004 and HDR-9003.
25	Key words: stroke; genetic correlation: validation: routinely collected health data;
26	
27	
28	
29	

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

30 Abstract

31	Background: Stroke in UK Biobank (UKB) is ascertained via linkages to coded administrative
32	datasets and self-report. We studied the accuracy of these codes using genetic validation.
33	Methods: We compiled stroke-specific and broad cerebrovascular disease (CVD) code lists (Read
34	V2/V3, ICD-9/-10) for medical settings (hospital, death record, primary care) and self-report.
35	Among 408,210 UKB participants we identified all with a relevant code, creating 12 stroke
36	definitions based on the code type and source. We performed genome-wide association studies
37	(GWASs) for each definition, comparing summary results against the largest published stroke
38	GWAS (MEGASTROKE), assessing genetic correlations, and replicating 32 stroke-associated loci.
39	Results: Stroke case numbers identified varied widely from 3,976 (primary care stroke-specific
40	codes) to 19,449 (all codes, all sources). All 12 UKB stroke definitions were significantly correlated
41	with the MEGASTROKE summary GWAS results (rg 0.81-1) and each other (rg 0.4-1). However,
42	Bonferroni-corrected confidence intervals were wide, suggesting limited precision of some results
43	Six previously reported stroke-associated loci were replicated using ≥1 UKB stroke definitions.
44	Conclusions: Stroke case numbers in UKB depend on the code source and type used, with a 5-fold
45	difference in the maximum case-sample size. All stroke definitions are significantly genetically
46	correlated with the largest stroke GWAS to date.
47	
48	
49	

- 50
- 51
- 52

53 Introduction

54	UK Biobank (UKB) is a prospective population-based cohort study with extensive phenotype and
55	genotype information on >500,000 participants from England, Scotland and Wales
56	(www.ukbiobank.ac.uk). It is an open access resource, established to facilitate research into the
57	determinants of a wide range of health outcomes, particularly those relevant in middle and older
58	age (Sudlow, 2015). An example of such a disease is stroke, the second most common cause of
59	death worldwide and a major global cause of disability (Lozano, 2012).
60	Disease outcomes in UKB are ascertained chiefly via linkages to routinely collected, coded,
61	national administrative health datasets. In addition, data on self-reported medical conditions was
62	collected at recruitment. However, to use these data appropriately, researchers need to select
63	which particular disease codes to use for their study and have an understanding of their accuracy.
64	For example, to identify stroke cases, existing codes can be divided into those that are stroke-
65	specific and those that fall under the broad cerebrovascular disease (CVD) category. Stroke-
66	specific codes are used to code acute stroke events where the clinician is confident about the
67	diagnosis and can usually assign a subtype. In contrast, broad CVD codes also capture cases with:
68	(i) phenotypes which pose a high risk for a subsequent stroke (e.g. a code for transient ischaemic
69	attack, an unruptured aneurysm, or carotid artery stenosis); (ii) a past history of stroke with
70	residual symptoms (e.g. a code for sequelae of cerebral infarction); (iii) events where there may be
71	some diagnostic uncertainty (e.g. a code for unspecified cerebrovascular disease); and (iv)
72	intracranial haemorrhages other than intracerebral or subarachnoid haemorrhage (e.g., extradural
73	or subdural haemorrhages, which most clinicians consider different from stroke). Including codes
74	from the broad CVD category will therefore significantly increase the overall number of cases
75	identified, but while this is likely to include at least some misclassified true acute stroke cases,
76	non-stroke cases will also be included.

In a systematic review of studies validating stroke code accuracy from case-note review, the 77 overall positive predictive value (proportion of true-positive cases among all identified cases) for 78 identifying acute stroke cases was consistently >70% for stroke-specific codes, dropping to <50% in 79 80 many studies when broad CVD codes were included (Woodfield, 2015 & Rannikmäe, 2020). For self-reported stroke events, the positive predictive value ranged from 22% to 87% across different 81 82 studies, making it hard to draw firm conclusions (Woodfield, 2015). While case-note review for 83 code validation is often considered a gold-standard, this method also has its limitations. It is timeconsuming and labour-intensive, so can only be achieved in relatively small numbers of cases, with 84 limited precision of the results. In addition, the results rely on: (i) accessing the complete relevant 85 medical record; (ii) the detail and quality of the medical record; (iii) the qualification of the person 86 reviewing the notes; (iv) the inter-adjudicator agreement, which we know is not perfect even 87 between highly specialised clinicians; and (v) the consistency of results across different healthcare 88 89 settings/providers (Liberman, 2018). We set out to supplement current knowledge about the accuracy of stroke codes with a method 90 91 making use of large-scale genetic data, which we refer to as 'genetic validation'. The fundamental 92 idea is to use existing knowledge of genetic associations with a disease (in this case acute stroke), 93 to assess how well various potential code lists capture people who truly have this disease, which in turn could be used to harmonise disease definitions across cohorts and health systems (Manolio, 94 2020). If the code list captures true-positive cases, we would expect the genetic associations that 95 result from stroke cases identified through coded data to closely mirror the genetic association 96 97 results from previous studies of stroke.

98

99

100

101 Methods

102 Study setting

103	We included all 408,210 UKB white British ancestry participants in this study. We restricted our
104	analyses to this ancestry subgroup because it covers 94% of the UKB participants and allowed us
105	to achieve a good balance between attaining sufficient case numbers while reducing population
106	stratification and analytic complexity. As part of the UK Biobank recruitment process, informed
107	consent was obtained from all individual participants included in the study. At the time of the
108	study, UKB had linked hospital admissions and death registry administrative coded data available
109	for all participants, and primary care administrative coded data for 47% of the cohort (191,146),
110	covering the time period up to March and September 2019, respectively (S1 Table). In addition, all
111	participants self-reported pre-existing health conditions during an interview at recruitment. The
112	subset of the cohort with primary care data available was similar to the whole cohort with respect
113	to age at recruitment, sex and Townsend deprivation index (S2 Table).
114	Identifying stroke cases in UKB
115	We compiled stroke-specific and broad cerebrovascular disease (CVD) code lists for each medical
116	setting (hospital admission, death record, primary care) and self-report. This process was informed
117	by previously published codes where available (Woodfield, 2015 & Rannikmäe, 2020),
118	supplemented by the selection of additional codes by expert clinicians (authors KR, CLMS, ED, RW)
119	on discussion and mutual agreement. This resulted in a total of 8 code lists, covering the ICD-
120	9/ICD-10, Read Version 2, Clinical Terms Version 3 (Read Version 3) and UKB self-report illness
121	coding systems (S3 Table).
122	Next, we identified all participants with a relevant code from any of the code lists and created 12

different ways of defining stroke cases in UKB based on the code type (stroke-specific, broad CVD)
and source (hospital admission, death record, primary care, self-report). This resulted in 12

partially overlapping case-control groups, where cases were all the individuals with a stroke code

126 for the particular stroke definition, and all the remaining participants acted as controls. A specific

- 127 UKB participant could therefore be a stroke case for one definition and a control for another
- 128 definition.

129 Genome-Wide Association Studies

- 130 We performed 12 genome-wide association studies (GWASs), one for each case-control set (i.e. for
- each definition of stroke cases and their controls). We applied a linear mixed model method using
- the BoltLMM software package (v2.3.4) software (Loh, 2015). We included the following as
- 133 covariates: genotyping array, UKB assessment centre, sex, age at recruitment, and principal
- 134 components one to ten. We filtered the results for single nucleotide polymorphisms (SNPs) with
- an imputation quality INFO score \geq 0.9 and minor allele frequency \geq 1%. After filtering the results
- 136 for SNP imputation quality and minor allele frequency, we included 9,524,428 SNPs. We converted
- 137 the linear mixed model effects to odds ratios using R code provided in
- 138 <u>https://shiny.cnsgenomics.com/LMOR/</u> (Lloyd-Jones, 2018).

139 Analyses of GWAS results

- 140 We compared summary results from our 12 GWASs against the largest published stroke GWAS
- 141 meta-analysis project the MEGASTROKE study. The MEGASTROKE study is a meta-analysis of 29
- stroke GWASs (17 including individuals of European ancestry) and does not include UKB data.
- 143 Almost all studies included in MEGASTROKE (covering >95% included cases) required the stroke
- 144 diagnosis to be confirmed by a medical professional or required evidence of stroke from >1
- source, even if the initial case ascertainment included using administrative codes (Malik, 2018). All
- analyses were done using R software version 3.6.2.
- 147 Genetic correlation with the MEGASTROKE study results

- 148 We applied a high-definition likelihood method using the HDL software (Ning, 2020) to assess the
- 149 genetic correlation between our GWAS results using the 12 stroke definitions, and the
- 150 MEGASTROKE study GWAS summary results for any stroke subtype in European samples. Genetic
- 151 correlation (rg) is the proportion of variance that two stroke definitions share due to genetic
- 152 causes. A genetic correlation of 0 implies that the genetic effects on one definition are
- independent of the other, while a correlation of 1 implies that all of the genetic influences on the
- two definitions are identical. We assessed if the correlation was significantly different from 0 and
- 155 from 1, setting the p-value significance threshold to 0.0042 after a Bonferroni correction for the 12
- tests. We displayed the results (correlation measured as rg) on a heatmap. We also display
- 157 Bonferroni corrected confidence intervals to aid interpretation.
- 158 Genetic correlation within our study definitions
- 159 We then used the HDL software to assess genetic correlations within our study across the 12
- definitions. We set the significance threshold to 0.0024 after a Bonferroni correction for 7
- 161 independent non-overlapping case-control definitions (definitions not in bold in Table 1), resulting
- in 21 correlation tests. We also display Bonferroni corrected confidence intervals to aid

163 interpretation.

164 *Replicating the MEGASTROKE study stroke-significant loci*

165 The MEGASTROKE study identified 32 genetic loci significantly associated with stroke. We

identified these loci (the lead SNP for each locus) in our GWAS summary results and considered a

- 167 locus to be replicated (i.e. also significantly associated with the respective stroke definition in our
- data) if the p-value of association in our GWAS was <0.00156 (Bonferroni corrected for 32 loci).
- 169 We compared the number of replicated loci across our summary definitions. We compared the
- 170 effect sizes of the associations between MEGASTROKE trans-ethnic and European ancestry GWASs
- and our GWAS summary results. Where the lead SNP was not available in our data, we identified

- 172 SNPs in moderate LD ($r^2 > 0.7$ in the 1000 Genomes GBR population using the Ensembl LD
- 173 calculator https://www.ensembl.org/Homo_sapiens/Tools/LD) with the lead SNP, and if any SNPs
- in LD available in our data were identified, we examined their associations instead. We displayed
- 175 results for five of our summary definitions of stroke cases and their controls: stroke-specific code
- 176 from any medical setting; broad CVD code from any medical setting; stroke-specific or broad CVD
- 177 code from any medical setting; specific or non-specific self-reported stroke event; any code or self-
- 178 reported event. We highlighted significantly associated (i.e. replicated) loci.
- 179 We also calculated our expected power to replicate the 32 loci using the Genetic Association Study
- 180 (GAS) Power Calculator (http://csg.sph.umich.edu/abecasis/gas_power_calculator/index.html),
- assuming a stroke prevalence of 2.26% and inputting the disease allele frequency and genotype
- relative risk estimates from the MEGASTROKE publication Table 1 (Malik, 2018).
- 183 Results

184 Stroke cases in UKB

- 185 The number of relevant codes for identifying stroke cases varied widely depending on the coding
- 186 system (ICD versus Read versus self-report) and code type (stroke-specific versus broad CVD code)
- 187 from less than five codes for a specific self-reported stroke event, to >500 codes when including
- all possible codes across all coding systems. The stroke-specific and broad cerebrovascular disease
- 189 (CVD) code lists for each medical setting and self-report are shown in S3 Table.
- 190 The number of stroke cases identified among the 408,210 participants also varied widely
- 191 depending on the code type and source used from 3,976 cases in primary care when using
- 192 stroke-specific codes, to 19,449 cases when including all possible code combinations (stroke-
- specific and broad CVD) across all sources (hospital admission, death record, primary care, self-
- 194 report) (Table1).

The code source for cases with a stroke-specific code was: self-report only in 27%, primary care only for 9%, hospital/death record code only for 29%, and >1 source for 35% (S1 Figure). The code source for cases with either a stroke-specific or a broad CVD code was: self-report only in 14%, primary care only for 15%, hospital/death record code only for 34%, and >1 source for 37% (S1 Figure). These proportions are calculated based on the primary care data being currently available only for ~50% of the participants, and so will change when primary care data for the whole cohort become available.

202 The overall proportion of prevalent codes (i.e. first code predates participant's recruitment to

203 UKB) versus incident codes (i.e. first code date occurs after participant's recruitment to UKB) was

the same for stroke-specific and broad CVD categories: 38% prevalent versus 62% incident codes.

205 These proportions are dependent on the updates to different linked health datasets and the

206 proportion of incident codes will continue to increase with increasing duration of follow up. (S1

207 Table).

208 Mean and median age at recruitment were higher among stroke cases (for all stroke definitions) than for the whole cohort of UKB participants (mean age 61 to 62 years vs 57 years; median age 209 62 to 63 years vs 58 years). Mean and median age at the time of stroke (in case of multiple events, 210 age at the earliest event was taken) was higher for coded diagnoses from the medical setting 211 compared to self-reported events (mean age 62 years vs 53 years, median age 63 years vs 55 212 213 years, respectively). This is to be expected, considering that all self-reported events were recorded at the time of recruitment, whereas medical codes also capture diagnoses after recruitment 214 during follow up. The proportion of women was lower among stroke cases than across all UKB 215 participants (43% for those with any medical setting or self-reported code vs 54% for all UKB). This 216 is to be expected as age-specific incidence rates are substantially lower in women than men in 217 218 younger and middle-age groups, but these differences narrow down so that in the oldest age

- groups, incidence rates in women are approximately equal to or even higher than in men (Virani,
- 220 2020). (Table 1).
- 221 Analyses of GWAS results
- 222 Genetic correlation with the MEGASTROKE study results
- 223 All 12 UKB stroke definitions were significantly correlated with the MEGASTROKE summary GWAS
- results, with genetic correlations (rg) ranging from 0.81 to 1, and confidence intervals overlapping.
- The p-values for difference from 1 were not significant, compatible with perfect correlation.
- However, the Bonferroni corrected CIs were wide, especially for 5 of the 12 tests, where the lower
- 227 confidence limit was <0.7, limiting the precision of some of these results (Figure 1, Figure 2, S4
- 228 Table).
- 229 Genetic correlation within our study definitions
- 230 The UKB summary definitions in our study were all significantly correlated with each other (all p-
- values significantly different from 0), with rg ranging from 0.4 to 1. Again, the Bonferroni corrected
- 232 CIs were wide, with the lower confidence limit even suggesting the possibility of a negative
- correlation for two comparisons. (Figure 1, Figure 2, S5 Table).
- 234 Replicating the MEGASTROKE study stroke-significant loci

235 Within our GWASs, 6 of the 32 previously reported stroke-associated loci were replicated by one

or more definitions. Analyses using stroke-specific codes and analyses using any code or self-

reported event both replicated the biggest number of known stroke loci (5 of 32). The power from

- additional cases for the latter category did not result in replicating more loci than stroke-specific
- 239 codes alone. However, for three of the five replicated loci, the p-values were smaller in the larger
- 240 dataset (analyses using any code or self-reported event) suggesting a more robust replication
- when using the broadest definition of stroke in UKB. Within our data, effect sizes (expressed as

- 242 odds ratios) were similar across the stroke definitions, with overlapping Bonferroni corrected
- 243 confidence intervals.
- For two of the six replicated loci (*PITX2* and *HDAC9–TWIST1*), the effect size of the association
- 245 (odds ratio) was bigger in the MEGASTROKE dataset than in our data (across all five summary
- 246 stroke definitions). These two loci are known to be associated with particular stroke subtypes –
- 247 *PITX2* with cardioembolic and *HDAC9–TWIST1* with large artery stroke [10]. (Figure 3, Table 2, S6
- 248 Table).
- Power calculations suggested we had ≥80% power to replicate all 32 loci for the any code or self-
- reported event definition, while having \geq 80% power for only 11/32 loci for the definition
- 251 including a stroke-specific code from any medical setting. (S7 Table).

252 Discussion

253 Our analyses show, that depending on the code source and type used for identifying stroke cases in the UKB, the currently achieved maximum case-sample size can range from ~4,000 to ~20,000 -254 255 a remarkable 5-fold difference. We go on to demonstrate, that regardless of the code source and 256 type used, the resulting GWAS summary results are significantly genetically correlated with the largest stroke GWAS to date. Finally, when we try to replicate known stroke-significant loci in our 257 data, both stroke-specific codes from any medical setting as well as a broad definition including 258 any code or self-reported event, replicate 5 of the 32 loci. Replication generated broadly similar 259 effect sizes for all but 2 stroke subtype specific loci, which is likely explained by our dataset 260 261 including a mix of stroke subtypes. Another possible explanation is the "winner's curse" 262 phenomenon (i.e. the estimated effect of a marker allele from the initial study reporting the marker-allele association is often exaggerated relative to the estimated effect in follow-up 263 264 studies).

265 The correlation of all definitions with the MEGASTROKE study results suggests one or more of the following: (i) all definitions retrieve true-positive acute stroke cases, meaning that broad CVD 266 267 codes include additional true-positive cases not identified by stroke-specific codes; (ii) cases coded with a broad CVD code have not necessarily suffered an acute stroke, but represent a range of 268 phenotypes with a similar genetic architecture to acute stroke (e.g. previous research has shown 269 at least one overlapping locus for carotid artery disease and acute stroke (Malik, 2018)); (iii) the 270 271 MEGASTROKE study includes some misclassified broad CVD cases as false-positive acute stroke cases. It is most likely that a combination of these factors is contributing to our findings, but we 272 are unable to dissect their separate contributions in the current study. 273

Previous case-note validation studies suggested that broad CVD codes are better at identifying the
broad conditions they signify as opposed to ascertaining acute stroke cases (McCormick, 2015),

supporting a role for option two above. An example of this would be a case-note review of 276 patients with a code for an unruptured intracranial aneurysm or carotid artery stenosis confirming 277 that the diagnosis was also most likely an unruptured intracranial aneurysm or carotid artery 278 stenosis, rather than rather than the reviewing clinician deciding it was an acute stroke that had 279 been miscoded as an unruptured intracranial aneurysm or carotid artery stenosis. 280 281 Despite the definition using any code or self-reported event increasing the sample size by more than two-fold compared to the definition using only stroke-specific codes from a medical setting, it 282 did not replicate a higher number of known stroke-associated loci. This could suggest that there is 283 still insufficient power to replicate additional loci using any of our definitions despite power 284 285 calculations suggesting ≥80% power for all loci. Also, associations for nine of the 32 loci in 286 MEGASTROKE were only found for specific stroke subtypes and 11 of the 32 loci were significant in analyses including only ischaemic stroke cases, the proportions of which are unlikely to be 287 identical between the two datasets. For example, the MEGASTROKE study sample included 90% 288 confirmed ischaemic stroke cases. The stroke subtype breakdown among the UKB participants is 289 available only for stroke-specific codes from hospital, death record and self-reported data (UK 290 291 Biobank datafields '42009', '42011' and '42013') and shows a proportion of confirmed ischaemic stroke cases of 47%, with 10% cases being intracerebral haemorrhage and 11% subarachnoid 292 haemorrhage and the remainder of unspecified stroke subtype. Alternatively, it could also suggest 293 that the additional cases identified by using any code or self-report are not true-positive stroke 294 cases or that some of these known stroke-associated loci are false-positive findings. 295 Self-reported cases (both stroke-specific and broad CVD) also showed a close genetic correlation 296 with the MEGASTROKE study, supporting the use of self-report as a means of identifying additional 297 stroke cases in the UKB. This was so despite the highly variable results from previous case-note 298 299 based validation studies of self-report for ascertaining stroke cases. Studying this by case-note

validation in UKB itself would be challenging, given the difficulties accessing NHS records which
predate recruitment by many years and the fact that participants may have moved between UK
regions during their life-course. Other studies have also reported a close genetic correlation
between a wide range of self-reported diseases and medical setting diagnoses. Examples include
both acute and chronic conditions (e.g. depression, myocardial infarction, rheumatoid arthritis)
(Wray, 2018; Howard, 2019; DeBoever, 2020).

For some of our definitions, the rg was >1. The estimated rg is a combination of the true rg and 306 307 variation. When the true rg is close to the boundary (-1 or 1) and/or variation is large, the 308 estimated rg can go beyond the boundary (Ning, 2020). In rg estimation, some common reasons 309 for generating large variation are: (i) at least one of the h² estimates is very low; (ii) small sample 310 size; (iii) many SNPs in the reference panel are absent in one of the two GWASs; (iv) there is a severe mismatch between the GWAS population and the population for computing reference 311 panel. We can exclude the last two options, and the small sample size is therefore the likely 312 explanation. 313

In our analyses, the case-control groups were partially overlapping and a specific UKB participant 314 could therefore be a stroke case for one definition and a control for another definition. We used 315 this study design to mimic the 'real world' situation, creating binary case-control definitions based 316 on each code list. In theory this could reduce the power of some of the analyses, since it means 317 controls can end up including some true-positive stroke cases. However, in reality it is unlikely to 318 319 have a significant effect given the overall large number of controls. For example, for analyses using 320 stroke-specific codes from any medical setting, just over 2% of controls have a broad CVD code and/or have self-reported a stroke event. 321

We used BoltLMM for running the GWAS (Loh, 2015). Our case-fraction ranged from 1% to 5% depending on the case-definition and we limited our analyses to SNPs with a minor allele

frequency of at least 1%. Based on simulations done using BoltLMM, the authors of the software 324 suggest that with these case-fraction and minor allele frequency parameters, they did not find a 325 326 statistically significant inflation of type I error rates (Supplementary table 8 in Loh, 2015). 327 The strengths of our study are: (i) we included - and have made available to re-use - a clinically 328 informed, comprehensive set of codes across all relevant coding systems; (ii) we compared our results against the largest stroke GWAS to date; (iii) we used multiple methods for comparison 329 330 accounting for both GWAS significant loci but also SNPs across the whole genome – i.e. correlation and replication; (iv) we have added novel data to what is already known from case-note validation. 331 332 Our study also has some limitations: (i) some of our definitions included relatively small case numbers compared to the MEGASTROKE study, reducing our power to replicate known loci; (ii) 333 uneven numbers across definitions not allowing direct comparisons, but rather reflecting the real-334 335 world situation; (iii) our definitions included the subarachnoid haemorrhage stroke subtype codes, whereas the MEGASTROKE study did not, resulting in a slightly different mix of stroke cases; (iv) 336 337 the UKB participants' demographic characteristics differ from those of the UK general population 338 with evidence of a healthy-volunteer selection bias, which needs to be considered when extrapolating these results to other settings (Fry, 2017). 339 340 We have shown that the selection of codes and code sources used to ascertain stroke cases has a

major impact on the overall stroke case numbers in the UKB. Given the close genetic correlation between stroke cases identified using broad CVD codes, self-report, and physician-confirmed stroke cases, we suggest that for studies accepting of more crude stroke and cerebrovascular disease outcomes, researchers may wish to include all codes and self-reported events for increased power. Alternatively, this information is also helpful in informing the selection of controls for various studies. Including a large number of broad CVD coded cases among controls might weaken any association seen for certain study designs. However, since we cannot exclude

- 348 the effects of a shared genetic control of broad CVD phenotypes and acute stroke, this evidence is
- 349 not sufficient to support using broad CVD codes in studies that need to define acute stroke
- 350 outcomes very accurately (e.g. clinical trials).
- 351 Further research is needed: to better understand the underlying reasons for the close genetic
- 352 correlation between stroke-specific and broad CVD codes; to dissect the underlying explanation
- 353 for our results with targeted case-note validation; and to replicate our results in other datasets. In
- addition, more data is needed on the accuracy of different coding systems for identifying specific
- 355 pathological stroke subtypes (ischaemic stroke versus intracerebral haemorrhage versus
- subarachnoid haemorrhage) and aetiological stroke subtypes (e.g., small vessel disease versus
- 357 large artery disease versus cardioembolic stroke versus other / unknown cause).

- 358 Acknowledgements: This work was undertaken under a UKB project 2532 "UK Biobank Stroke
- 359 Study (UKBiSS): developing an in-depth understanding of the determinants of stroke and its
- 360 subtypes." Authors acknowledge Dr Spiros Denaxas, UCL, for his valuable comments on the
- 361 manuscript. The MEGASTROKE project received funding from sources specified at
- 362 <u>http://www.megastroke.org/acknowledgments.html</u> and the author list for the MEGASTROKE
- 363 consortium is added in Appendix 1.
- 364 Funding: K Rannikmae is funded by Health Data Research UK Rutherford fellowship
- 365 MR/S004130/1. AF is funded by BHF award RE/18/5/34216. AT is funded by HDR-UK awards HDR-
- 366 9004 and HDR-9003. The funders had no role in study design, data collection and analysis, decision
- 367 to publish, or preparation of the manuscript
- 368 **Disclosures:** Authors report no competing interests.
- 369 Author contributions: All authors made substantial contributions to the conception or design of
- 370 the work; or the acquisition, analysis, or interpretation of data for the work; AND drafting the
- 371 work or revising it critically for important intellectual content; AND final approval of the version to
- 372 be published; AND agreement to be accountable for all aspects of the work in ensuring that
- 373 questions related to the accuracy or integrity of any part of the work are appropriately
- investigated and resolved.
- 375 Data sharing: The data that supports the findings of this study are available in the supplementary
 376 material of this article.
- 377
- 378
- 379
- 380

381 References:

382	1.	Sudlow, C. L. M., Gallacher, J., Allen, N., Beral, V., Burton, B., Danesh, J. et al. (2015). UK
383		Biobank: an open access resource for identifying the causes of a wide range of complex
384		diseases of middle and old age. PLoS Medicine. 31;12(3):e1001779.
385	2.	Lozano, R., Naghavi, M., Foreman, K., Lim, S., Shibuya, K., Aboyans, V. et al. (2010). Global
386		and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a
387		systematic analysis for the Global Burden of Disease Study 2010. Lancet. 380(9859):2095-
388		2128.
389	3.	Woodfield, R., Grant, I., UK Biobank Stroke Outcomes group, UK Biobank Follow-Up and
390		Outcomes Working Group, Sudlow, C. L .M. (2015). Accuracy of Electronic Health Record
391		Data for Identifying Stroke Cases in Large-Scale Epidemiological Studies: A Systematic
392		Review from the UK Biobank Stroke Outcomes Group. PLoS One. 10(10):e0140533.
393	4.	Rannikmäe, K., Ngoh, K., Bush, K., Al-Shahi Salman, R., Doubal, F., Flaig, R. et al. (2020).
394		Accuracy of identifying incident stroke cases from linked health care data in UK Biobank.
395		<i>Neurology.</i> 95(6):e697-e707.
396	5.	Woodfield, R., UK Biobank Stroke Outcomes Group, UK Biobank Follow-up and Outcomes
397		Working Group, Sudlow, C. L. M. (2015). Accuracy of Patient Self-Report of Stroke: A
398		Systematic Review from the UK Biobank Stroke Outcomes Group. Plos One.
399		10(9):e0137538.
400	6.	Liberman, A. L., Rostanski, S. K., Ruff, I. M., Meyer, A. N. D., Maas, M. B., Prabhakaran, S.
401		(2018). Inter-rater Agreement for the Diagnosis of Stroke Versus Stroke Mimic. Neurologist.
402		23(4):118-121.

- Manolio, T.A., Goodhand, P., Ginsburg, G. (2020). The International Hundred Thousand Plus
 Cohort Consortium: integrating large-scale cohorts to address global scientific challenges.
 Lancet Digital Health. 2(11):e567-e568.
- 406 8. Loh, P-R., Tucker, G., Bulik-Sullivan, B. K., Vilhjálmsson, B. J., Finucane, H. K., Salem, R. M. et
- 407 al. (2015). Efficient Bayesian mixed-model analysis increases association power in large
 408 cohorts. *Nature Genetics*. 47(3):284-290.
- 409 9. Lloyd-Jones, L. R., Robinson, M.R., Yang, J., Visscher, P. M. (2018). Transformation of
- 410 Summary Statistics from Linear Mixed Model Association on All-or-None Traits to Odds
- 411 Ratio. *Genetics*. 208(4):1397-1408.
- 412 10. Malik, R., Chauhan, G., Traylor, M., Sargurupremraj, M., Okada, Y., Mishra, A. et al. (2018).
- 413 Multiancestry genome-wide association study of 520,000 subjects identifies 32 loci

associated with stroke and stroke subtypes. *Nature Genetics.* 50(4):524-537.

- 415 11. Ning, Z., Pawitan, Y., Shen, X. (2020). High-definition likelihood inference of genetic
 416 correlations across human complex traits. *Nature Genetics*. 52:859–864.
- 417 12. Virani, S. S., Alonso, A., Benjamin, E. J., Bittencourt, M. S., Callaway, C. W., Carson, A.P. et
- 418 al. (2020). Heart Disease and Stroke Statistics 2020 Update: A Report From the American
 419 Heart Association. *Circulation*. 141(9):e139.

420 13. McCormick, N., Bhole, V., Lacaille, D., Avina-Zubieta, J. A. (2015). Validity of Diagnostic
421 Codes for Acute Stroke in Administrative Databases: A Systematic Review. *PLoS One*.
422 10(8):e0135834.

- 423 14. Wray, N. R., Ripke, S., Mattheien, M., Trzaskowski, M., Byrne, E. M., Abdellaoui, A. et al.
- 424 (2018). Genome-wide association analyses identify 44 risk variants and refine the genetic
 425 architecture of major depression. *Nature Genetics*. 50:668–681.

426	15. Howard, D. M., Adams, M. J., Clarke, T. K., Hafferty, J. D., Gibson, J., Shirali, M. et al. (2019).
427	Genome-wide meta-analysis of depression identifies 102 independent variants and
428	highlights the importance of the prefrontal brain regions. Nature Neuroscience. 22:343–
429	352.
430	16. DeBoever, C., Tanigawa, Y., Aguirre, M., McInnes, G., Lavertu, A., Rivas, M. A. (2020).
431	Assessing Digital Phenotyping to Enhance Genetic Studies of Human Diseases. American
432	Journal of Human Genetics. 106(5):611-622.
433	17. Fry, A., Littlejohns, T. J., Sudlow, C. L. M., Doherty, N., Adamska, L., Sprosen, T. et al. (2017).
434	Comparison of Sociodemographic and Health-Related Characteristics of UK Biobank
435	Participants With Those of the General Population. American Journal of Epidemiology.
436	186(9):1026-1034.
437	
438	
439	
440	
441	
442	
443	
444	
445	
446	
447	

Table 1. Number and demographic characteristics of stroke cases identified in UKB

STROKE DEFINITION	NUMBER OF CASES	NUMBER OF CONTROLS	Mean (median) age at recruitment (years)	Mean (median) age; age range at stroke (years)	Sex (% female)
Stroke-specific code from hospital/death records	6,887	401,323	61 (63)	63 (64); 31 to 79	40
Stroke-specific code from primary care	3,976	404,234	61 (63)	59 (61); 1 to 79	41
Stroke-specific code from any medical setting	8,665	399,545	61 (63)	61 (63); 1 to 79	41
Broad CVD code from hospital/death records	5,725	402,485	62 (63)	64 (65); 31 to 79	43
Broad CVD code from primary care	4003	404,207	62 (63)	62 (63); 1 to 79	41
Broad CVD code from any medical setting	8,085	400,125	62 (63)	63 (64); 1 to 79	44
Stroke-specific or broad CVD code from hospital/death records	12,612	395,598	61 (63)	63 (64); 31 to 79	41
Stroke-specific or broad CVD code from primary care	7,979	400,231	62 (63)	60 (62); 1 to 79	41
Stroke-specific or broad CVD code from any medical setting	16,750	391,460	62 (63)	62 (63); 1 to 79	42
Specific self-reported stroke event	5,915	402,295	61 (62)	53 (55); 0 to 70	41
Specific or non-specific self-reported stroke event	7,536	400,674	61 (63)	53 (55); 0 to 70	42
Any code or self-reported event	19,449	388,761	61 (63)	60 (61); 0 to 79	43
Across all UKB participants	408	,210	57 (58)	Not applicable	54

49 50 We considered code and self-reported event age missing if it predated the date of birth, contained a negative value, or was recorded by UKB as unreliable or missing – this affected 0.3% to 2.1% cases depending on the stroke definition. CVD: cerebrovascular disease;

51 **Table 2. MEGASTROKE stroke-significant loci replicated using UKB stroke definitions**

Known stroke genetic locus	Significantly associated stroke type in MEGASTROKE	MEGASTROKE European meta- analyses N = 40,585*	MEGASTROKE transethnic meta-analyses N = 67,162 †	Stroke-specific code from any medical setting N = 8,665	Broad CVD code from any medical setting N = 8,085	Stroke-specific or Broad CVD code from any medical setting N = 16,750	Specific or non- specific self- reported stroke event N = 7,536	Any code or self-reported event N = 19,449
CHR4: rs13143308	Cardio-embolic	1.34 (1.28-1.40)	1.32 (1.27-1.37)	1.09 (1.05-1.13)	1.06 (1.02-1.1)	1.08 (1.05-1.11)	1.04 (0.995-1.08)	1.07 (1.04-1.1)
(PITX2)	stroke	5.2x10-41	1.9x10-47	7.5x10-6	0.0036	1x10-7	0.08	3x10-7
CHR7: rs2107595	Large-vessel	1.27 (1.19-1.35)	1.21 (1.15-1.26)	1.07 (1.03-1.12)	1.03 (0.99-1.08)	1.05 (1.02-1.09)	1.08 (1.03-1.13)	1.06 (1.03-1.09)
(HDAC9–TWIST1)	stroke	1.4x10-13	3.7x10-15	1x10-3	0.12	4.7x10-4	8.9x10-4	1.1x10-4
CHR10: rs2295786	All stroke	1.05 (1.03-1.07)	1.05 (1.04-1.07)	1.07 (1.04-1.11)	1.01 (0.98-1.04)	1.04 (1.02-1.07)	1.04 (1.01-1.08)	1.05 (1.03-1.07)
(SH3PXD2A)	All Stroke	1.4x10-7	1.8x10-10	1.5x10-5	0.59	4x10-4	0.021	5.1x10-6
CHR12: rs3184504	All ischaemic	1.08 (1.06-1.10)	1.08 (1.06-1.10)	1.04 (1.01-1.07)	1 (0.97-1.03)	1.02 (1-1.05)	1.06 (1.03-1.1)	1.03 (1.01-1.05)
(SH2B3)	stroke	1.2x10-14	2.2x10-14	0.0096	0.83	0.04	1.9x10-4	0.0068
CHR9: rs635634	All ischaemic	1.08 (1.05-1.11)	1.07 (1.04-1.10)	1.08 (1.03-1.12)	1 (0.96-1.04)	1.04 (1.01-1.07)	1.1 (1.05-1.14)	1.05 (1.02-1.07)
(ABO)	stroke	9.2x10-9	6.9x10-3	1.8x10-4	0.86	0.0043	5.8x10-6	4.3x10-4
CHR9: rs7859727	All stroke	1.05 (1.03-1.07)	1.05 (1.03-1.07)	1.06 (1.03-1.09)	1.04 (1.01-1.07)	1.05 (1.03-1.07)	1.02 (0.98-1.05)	1.04 (1.02-1.06)
(Chr9p21)	All stroke	7.2x10-8	4.2x10-10	8.1x10-5	0.018	5.3x10-6	0.32	6.3x10-5
Summary: number replicated loci			5/32	0/32	4/32	3/32	5/32	

52 Significant associations are in bold in shaded boxes. CVD: cerebrovascular disease; CHR: chromosome; N: number;

53 [†] MEGASTROKE transethnic meta-analyses included 60,341 ischaemic stroke cases; 9,006 cardio-embolic stroke cases; 6,688 large-vessel stroke cases. MEGASTROKE European meta-analyses

54 included 34,217 ischaemic stroke cases; 7,193 cardio-embolic stroke cases; 4,373 large-vessel stroke cases.

perpetuity. All rights reserved. No reuse allowed without permission.

Figure 1. Genetic correlation of UKB stroke definitions with MEGASTROKE and each other.



457	Legend: V	Vhere the rg	was >1, we	rounded it to	o 1.
-----	-----------	--------------	------------	---------------	------

....

465 Figure 2. Confidence intervals of genetic correlation of UKB stroke definitions with MEGASTROKE

and each other. 466



467

Legend: The upper triangle displays Bonferroni corrected upper confidence intervals, and the 468

lower triangle displays Bonferroni corrected lower confidence intervals. Where the rg was >1, we 469

- rounded it to 1. 470
- 471
- 472
- 473
- 474

Figure 3. Megastroke stroke subtype-significant loci replicated using UK Biobank stroke

- definitions.
- Α.

CHR4: rs13143308 G=>T (PITX2)

		OR (95% CI)	P-value
Megastroke	•	1.32 (1.27-1.37)	1.86x10-47*
Stroke-specific code from hospital/death records	F- 4	1.1 (1.05-1.14)	1.7x10-5*
Stroke-specific code from primary care	k- - ₩	1.09 (1.03-1.15)	0.0028
Stroke-specific code from any medical setting	•	1.09 (1.05-1.13)	7.5x10-6*
Broad CVD code from hospital/death records	F <mark>M</mark> F-4	1.08 (1.04-1.14)	0.00047*
Broad CVD code from primary care	-1	1.05 (1-1.11)	0.07
Broad CVD code from any medical setting	•	1.06 (1.02-1.1)	0.0036
Stroke-specific or broad CVD code from hospital/death records	1	1.09 (1.06-1.13)	2.1x10-8*
Stroke-specific or broad CVD code from primary care	H <mark>and</mark> i	1.07 (1.03-1.11)	0.00062*
Stroke-specific or Broad CVD code from any medical setting	•	1.08 (1.05-1.11)	1.0x10-7*
Specific self-reported stroke event	F 🔤 -1	1.04 (0.99-1.09)	0.085
Specific or non-specific self-reported stroke event	•	1.04 (1-1.08)	0.08
Any code or self-reported event	•	1.07 (1.04-1.1)	3.0x10-7*
	0.9 1 1.1 1.2 1.3 OR (95% CI)	ר 1.4	

CHR7: rs2107595 G=>A (HDAC9-TWIST1)

			OR (95% CI)	P-value
Megastroke		-	1.21 (1.15-1.26)	3.65E-15*
Stroke-specific code from hospital/death records		F 🔚 -1	1.08 (1.03-1.13)	0.00099*
Stroke-specific code from primary care		⊦- ■ I	1.06 (1-1.13)	0.054
Stroke-specific code from any medical setting		•	1.07 (1.03-1.12)	0.001*
Broad CVD code from hospital/death records	ŀ	-1	1.03 (0.98-1.09)	0.21
Broad CVD code from primary care	1	🚾1	1.05 (0.99-1.11)	0.13
Broad CVD code from any medical setting	1	٠	1.03 (0.99-1.08)	0.12
Stroke-specific or broad CVD code from hospital/death records		H	1.06 (1.02-1.1)	0.00095*
Stroke-specific or broad CVD code from primary care		F -1	1.05 (1.01-1.1)	0.014
Stroke-specific or Broad CVD code from any medical setting		٠	1.05 (1.02-1.09)	0.00047*
Specific self-reported stroke event		⊦ ⊣	1.07 (1.02-1.12)	0.0094
Specific or non-specific self-reported stroke event		•	1.08 (1.03-1.13)	0.00089*
Any code or self-reported event		•	1.06 (1.03-1.09)	0.00011*
	0.9	1 1.1 1.2 1.3 1.4 OR (95% CI)		

487

488 Legend: MEGASTROKE odds ratio and p-value is shown for the analyses (European or trans-ethnic)

489 showing the lowest p-value